Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28065531 | 1.00 | KMT2A (0.51) | KMT2AP2RX7HCRTR1HCRTR2GAA | |
| SCHEMBL28065530 | 0.87 | KMT2A (0.44) | KMT2AP2RX7HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL7021591 | 0.87 | KMT2A (0.44) | KMT2AP2RX7HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL24434796 | 0.85 | KMT2A (0.57) | KMT2AP2RX7HCRTR1HCRTR2GAA | |
| SCHEMBL927807 | 0.85 | KMT2A (0.57) | KMT2AP2RX7HCRTR1HCRTR2GAA | |
| SCHEMBL2583749 | 0.85 | KMT2A (0.57) | KMT2AP2RX7HCRTR1HCRTR2GAA | |
| SCHEMBL17475298 | 0.84 | KMT2A (0.52) | KMT2AP2RX7GAAALDH1A1CYP2C9 | |
| SCHEMBL17475299 | 0.84 | KMT2A (0.52) | KMT2AP2RX7GAAALDH1A1CYP2C9 | |
| SCHEMBL8535575 | 0.83 | KMT2A (0.55) | KMT2AP2RX7GAAHDAC1HDAC6 | |
| SCHEMBL5166634 | 0.83 | KMT2A (0.55) | KMT2AP2RX7GAAHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-119301127-A | 6-Oxo-decahydro pyrrolo [1,2-a ] [1,5] diazocine and 6-oxo-decahydro-4H-pyrrolo [2,1-d ] [1,5] thiaazacine derivatives as modulators of STAT3 and STAT6 for the treatment of cancer and inflammatory conditions | 瑞克鲁迪克斯制药股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-105566447-B | The class peptide antagonists and its synthetic method of a kind of apoptosis inhibitory protein and application | 广东工业大学 | 2019-09-20 | — | — | CN | disclosed |
| CN-105585583-B | A kind of non-peptides apoptosis inhibitory protein antagonist and its synthetic method and application | 广东工业大学 | 2018-04-13 | — | — | CN | disclosed |
| CN-105585583-A | Non-peptide IAP (inhibitor of apoptosis protein) antagonist as well as synthetic method and application thereof | UNIV GUANGDONG TECHNOLOGY | 2016-05-18 | — | — | CN | disclosed |
| CN-105566447-A | Peptoid antagonist of anti-apoptosis protein and synthesis method and application of peptoid antagonist | UNIV GUANGDONG TECHNOLOGY | 2016-05-11 | — | — | CN | disclosed |
| EP-0574174-B1 | Angiotensin II antagonists | LILLY CO ELI (US) | 2003-08-13 | — | — | EP | disclosed |
| US-5693633-A | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5612360-A | AROMATIC N-HETEROCYCLIC COMPOUNDS AS HYPOTENSIVE AGENTS WITH ACID GROUPS, SULFONYLCARBOXAMIDES OR TETRAZOLE GROUPS | ELI LILLY AND COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5569768-A | USEFUL IN TREATING HYPERTENSION, CONGESTIVE HEART FAILURE, GLAUCOMA AND RENAL INSUFFICIENCY | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5556981-A | Angiotensin II antagonist intermediates | ELI LILLY AND COMPANY (US) | 1996-09-17 | — | — | US | disclosed |
| EP-0574174-A2 | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1993-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | STAT6, STAT3, STAT1 | KMT2A 1601/4885P2RX7 2744/4885HCRTR1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.